This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Malignant neoplasm of nasal cavity and middle ear, excluding all cancers (controls excluding all cancers)
C3_NASAL_CAVITY_MIDDLE_EAR_EXALLC
No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
3 out of 7 registries used, show all original rules. |
246 |
4. Check minimum number of eventsNone |
246 |
5. Include endpointsNone |
246 |
6. Filter based on genotype QC (FinnGen only) |
246 |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE_EXALLC
Extra metadata
- First used in FinnGen datafreeze
- DF12
Similar endpoints
↥List of similar endpoints to
Malignant neoplasm of nasal cavity and middle ear, excluding all cancers (controls excluding all cancers)
based on the number of shared cases.
Similar with more cases:
- Malignant neoplasm of nasal cavity and sinuses, excluding all cancers (controls excluding all cancers)
- Malignant neoplasm of respiratory system and intrathoracic organs, excluding all cancers (controls excluding all cancers)
- Malignant neoplasm, excluding all cancers (controls excluding all cancers)
- Malignant neoplasm, wide definition for exclusion
- Malignant neoplasm, wide definition for exclusion, excluding all cancers (controls excluding all cancers)
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 246 | 106 | 140 |
| Unadjusted period prevalence (%) | 0.05 | 0.04 | 0.06 |
| Median age at first event (years) | 65.53 | 64.21 | 66.53 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 139
- Matched controls
- 1390
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
C30.0
ICD-10 Finland
Malignant neoplasm: Nasal cavity
+∞
121.2
98
*
DHA10
NOMESCO Finland
Biopsy of cavity of nose
449.4
59.1
55
*
D14.0
ICD-10 Finland
Benign neoplasm: Middle ear, nasal cavity and accessory sinuses
351.0
49.5
47
*
130
Kela drug reimbursment
Malignant tumour
+∞
48.9
44
*
UDH02
NOMESCO Finland
Rhinopharyngoscopy
26.9
45.8
66
45
8070/3-C30.0
ICD-O-3
Squamous cell carcinoma, NOS, of nasal cavity
+∞
45.3
41
*
WF003
NOMESCO Finland
Adjuvant radiotherapy
+∞
45.3
41
*
DHB10
NOMESCO Finland
Excision of lesion of internal nose
+∞
41.8
38
*
WF002
NOMESCO Finland
Radical radiotherapy
468.6
36.8
35
*
H02AB02
ATC
dexamethasone; systemic
124.6
35.7
37
*
XX3DW
NOMESCO Finland
Time consuming IT work
38.2
34.1
43
16
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
30.3
28
*
A03FA01
ATC
metoclopramide; systemic, rectal
12.9
29.5
57
71
A04AA02
ATC
granisetron; systemic, transdermal
+∞
29.2
27
*
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
302.1
25.6
25
*
WZC00
NOMESCO Finland
Planning of intervention or health care consultation
7.1
24.4
78
212
8720/3-C30.0
ICD-O-3
Malignant melanoma, NOS, of nasal cavity
+∞
23.6
22
*
DM1DG
NOMESCO Finland
Paranasal sinuses and face area very extensive MRI examination with high intensity magnet
+∞
23.6
22
*
YA1BD
NOMESCO Finland
Extensive CT examination of head and neck for dose design of radiotherapy
+∞
23.6
22
*
A04AA01
ATC
ondansetron; systemic, rectal
43.3
23.1
28
8
UDM02
NOMESCO Finland
Sinoscopy
34.6
22.0
28
10
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
43.0
20.7
25
7
DNB30
NOMESCO Finland
Excision of lesion of ethmoidal sinus
+∞
20.3
19
*
ZX070
NOMESCO Finland
Intensity modified radiotherapy
+∞
20.3
19
*
YA1AD
NOMESCO Finland
CT examination of head and neck for dose design of radiotherapy
+∞
19.2
18
*
R04.0
ICD-10 Finland
Epistaxis
9.1
18.4
41
61
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
+∞
18.1
17
*
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
+∞
18.1
17
*
ZX090
NOMESCO Finland
Other technic of radiotherapy
205.1
18.0
18
*
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
32.3
17.1
22
8
D38.58
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour of other respiratory organ
+∞
17.0
16
*
DJB10
NOMESCO Finland
Excision of septum of nose
+∞
17.0
16
*
DM1BD
NOMESCO Finland
Extensive CT of paranasal sinuses and face area
192.1
16.9
17
*
N02AA05
ATC
oxycodone; systemic
7.4
16.3
42
77
DM1AD
NOMESCO Finland
CT of paranasal sinuses and face area
22.7
16.2
23
12
Z51.5
ICD-10 Finland
Palliative care
25.8
16.1
22
10
YA1VG
NOMESCO Finland
MRI examination of head and neck with high intesity magnet for dose design of radiotherapy
+∞
15.9
15
*
WF049
NOMESCO Finland
Radiotherapy of metastasis
+∞
15.9
15
*
EP1AE
NOMESCO Finland
Neck ultrasound examination
14.3
15.4
26
22
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
19.8
14.9
22
13
EN1BD
NOMESCO Finland
Very extensive CT examination of mouth and soft tissues of neck
41.0
14.8
18
5
L03AA02
ATC
filgrastim; parenteral
166.8
14.8
15
*
EP1CG
NOMESCO Finland
Extensive MRI examination of soft tissue of neck with high intesity magnet
166.8
14.8
15
*
C72.2
ICD-10 Finland
Malignant neoplasm: Olfactory nerve
+∞
13.8
13
*
WB103
NOMESCO Finland
Simple adjuvant cytostatic therapy
+∞
13.8
13
*
9522/3-C30.0
ICD-O-3
Olfactory neuroblastoma of nasal cavity
+∞
13.8
13
*
DMB20
NOMESCO Finland
Functional endoscopic opening of maxillary antrum
11.4
12.9
24
25
DPA30
NOMESCO Finland
Sphenotomy
77.1
12.8
14
*
C83.31
ICD-10 Finland
Diffuse lymphoma with large B cells
+∞
12.7
12
*
C78.0
ICD-10 Finland
Secondary malignant neoplasm of lung
+∞
12.7
12
*
YA1CD
NOMESCO Finland
Very extensive CT examination of head and neck for dose design of radiotherapy
+∞
12.7
12
*
WX408
NOMESCO Finland
General anesthesy, balanced
4.1
11.9
55
190
SAA03
NOMESCO Finland
Extended examination of mouth
3.7
11.6
70
300
DPC35
NOMESCO Finland
Extensive endoscopic excision of lesion or neoplasm extending to more than one paranasal sinus
+∞
11.6
11
*
DM1CG
NOMESCO Finland
Paranasal sinuses and face area extensive MRI examination with high intensity magnet
+∞
11.6
11
*
9680/3-C30.0
ICD-O-3
Diffuse large B-cell lymphoma, NOS, of nasal cavity
+∞
11.6
11
*
YX9AD
NOMESCO Finland
Other CT eamination for dose design of radiotherapy
+∞
11.6
11
*
JN4JR
NOMESCO Finland
Whole body extensive metabolic PET with CT
+∞
11.6
11
*
JN4KR
NOMESCO Finland
Whole body very extensive metabolic PET with CT
130.4
11.6
12
*
EN1AD
NOMESCO Finland
CT examination of mouth and soft tissues of neck
130.4
11.6
12
*
UDQ12
NOMESCO Finland
Flexible laryngoscopy
8.0
11.0
25
37
WX402
NOMESCO Finland
General anaesthesia
5.2
10.9
36
88
DHB40
NOMESCO Finland
Conchotomy
65.1
10.8
12
*
QAE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin in head or neck
12.0
10.7
19
18
AAE99
NOMESCO Finland
Other operation by cranial base approach
+∞
10.5
10
*
WD405
NOMESCO Finland
Simple antiboidy therapy of methastized malignancy
+∞
10.5
10
*
C78.7
ICD-10 Finland
Secondary malignant neoplasm of liver and intrahepatic bile duct
+∞
10.5
10
*
EB1HA
NOMESCO Finland
Panorama tomography of teeth and jaws or similar X-ray examination
3.2
9.7
73
357
DMA00
NOMESCO Finland
Biopsy of maxillary antrum
107.0
9.5
10
*
QA1S1
NOMESCO Finland
Photography of skin or subcutaneous tissue in head
107.0
9.5
10
*
EEB00
NOMESCO Finland
Partial excision of maxilla
+∞
9.5
9
*
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
+∞
9.5
9
*
WD325
NOMESCO Finland
Demanding therapy of methastized malignancy with biomodifiers
+∞
9.5
9
*
A07AA02
ATC
nystatin; oral
6.7
9.1
23
40
WX105
NOMESCO Finland
Surface analgesia on skin or mucosa
5.1
9.0
29
68
ZX095
NOMESCO Finland
Combined chemoradiotherapy
+∞
8.4
8
*
C61
ICD-10 Finland
Malignant neoplasm of prostate
+∞
8.4
8
*
D38.51
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour of other accessory sinus
+∞
8.4
8
*
DLW99
NOMESCO Finland
Other plastic operations on nose
+∞
8.4
8
*
C31.8
ICD-10 Finland
Malignant neoplasm: Overlapping lesion of accessory sinuses
+∞
8.4
8
*
C31.0
ICD-10 Finland
Malignant neoplasm: Maxillary sinus
+∞
8.4
8
*
R4190
NOMESCO Finland
Nutritional therapy
15.8
8.4
13
9
AA1BD
NOMESCO Finland
Extensive CT of head and brain
11.8
8.0
14
13
504
Kela drug reimbursment
Conditions requiring daily forced enteral nutrition
47.7
7.8
9
*
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
6.0
7.8
21
40
R22.0
ICD-10 Finland
Localized swelling, mass and lump, head
12.9
7.8
13
11
ZXC95
NOMESCO Finland
Use of surgical navigator
19.7
7.7
11
6
WW500
NOMESCO Finland
Blood transfusion
19.7
7.7
11
6
JN4BD
NOMESCO Finland
Extensive body CT
7.2
7.7
18
28
J34.8
ICD-10 Finland
Other specified disorders of nose and nasal sinuses
26.7
7.7
10
*
QAB10
NOMESCO Finland
Major dressing of wound of skin of head or neck
84.4
7.5
8
*
JDB10
NOMESCO Finland
Percutaneous gastrostomy
84.4
7.5
8
*
DMB30
NOMESCO Finland
Transmaxillary excision of lesion of maxillary antrum
84.4
7.5
8
*
YX9BD
NOMESCO Finland
Other extensive CT eamination for dose design of radiotherapy
+∞
7.4
7
*
DHB01
NOMESCO Finland
Partial excision of external nose
+∞
7.4
7
*
L01CB01
ATC
etoposide; systemic
+∞
7.4
7
*
WD305
NOMESCO Finland
Simple therapy of methastized malignancy with biomodifiers
+∞
7.4
7
*
WF004
NOMESCO Finland
Palliative radiotherapy
+∞
7.4
7
*
C43.39
ICD-10 Finland
Malignant melanoma of another or unspecified part of the face other or unspecified histology
+∞
7.4
7
*
C03.0
ICD-10 Finland
Malignant neoplasm: Upper gum
+∞
7.4
7
*
A04AD12
ATC
aprepitant; systemic
+∞
7.4
7
*
ZZQ00
NOMESCO Finland
Free microvascular graft of skin
+∞
7.4
7
*
PJD81
NOMESCO Finland
Excision of lymph nodes from upper part of neck
+∞
7.4
7
*
JN4AD
NOMESCO Finland
Body CT examination
9.0
7.0
14
17
JN5DR
NOMESCO Finland
PET-CT of upper body metabolism
42.2
6.8
8
*
DHB00
NOMESCO Finland
Excision of lesion of external nose
42.2
6.8
8
*
ZZR00
NOMESCO Finland
Flap of skin
23.9
6.8
9
*
J32.0
ICD-10 Finland
Chronic maxillary sinusitis
5.9
6.7
18
34
J01CR02
ATC
amoxicillin and beta-lactamase inhibitor; systemic
2.6
6.6
75
436
TPH07
NOMESCO Finland
Cathetrisation of artery
4.5
6.6
23
59
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
8.8
6.5
13
16
UDC00
NOMESCO Finland
Ear microscopy
5.0
6.5
20
45
C44.31
ICD-10 Finland
Basocellular carcinoma of the skin on another or unspecified part of the face
73.1
6.5
7
*
WZC30
NOMESCO Finland
Teaching
4.1
6.3
24
67
DMB00
NOMESCO Finland
Endonasal trephine of maxillary antrum
28.1
6.3
8
*
JN4CD
NOMESCO Finland
Very extensive body CT
28.1
6.3
8
*
8020/3-C30.0
ICD-O-3
Carcinoma, undifferentiated, NOS, of nasal cavity
+∞
6.3
6
*
AAE05
NOMESCO Finland
Nasoendoscopic closure of cerebrospinal fluid fistula
+∞
6.3
6
*
ZZF00
NOMESCO Finland
Graft of adipose tissue
+∞
6.3
6
*
L03AA14
ATC
lipegfilgrastim; parenteral
+∞
6.3
6
*
8200/3-C30.0
ICD-O-3
Adenoid cystic carcinoma of nasal cavity
+∞
6.3
6
*
WB113
NOMESCO Finland
Multiple adjuvant cytostatic therapy
+∞
6.3
6
*
D70.82
ICD-10 Finland
Drug-induced neutropenia
+∞
6.3
6
*
C79.5
ICD-10 Finland
Secondary malignant neoplasm of bone and bone marrow
+∞
6.3
6
*
C79.30
ICD-10 Finland
Secondary malignant tumor of the cerebrum
+∞
6.3
6
*
ZZG00
NOMESCO Finland
Graft of cartilage
+∞
6.3
6
*
ZXA05
NOMESCO Finland
Left side
2.7
6.2
48
225
WX110
NOMESCO Finland
Local anesthesy
2.5
6.1
95
642
WZC10
NOMESCO Finland
Extensive specialist consultion with written report
6.9
6.0
14
22
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
145
760
3.21
17.94
5.8
3.6
—
—
—
0
0
17
13
13.97
17.85
1.1
1.1
—
—
—
0
0
144
763
3.14
17.28
5.3
3.5
33.4
35.5
g/l
4.05
139
700
152
888
2.86
14.31
7.1
5.5
1.2
1.2
mmol/l
1.06
121
757
13
10
13.67
13.47
1.4
1.3
—
—
—
0
0
158
962
2.80
13.39
14.6
6.1
4.0
4.3
e9/l
1.12
143
836
139
801
2.69
13.03
6.4
4.9
1.2
1.2
mmol/l
0.43
132
701
81
386
2.64
10.78
2.2
1.9
—
—
—
0
0
12
12
10.46
10.52
2.0
2.1
—
—
—
0
0
105
587
2.38
9.74
5.7
2.1
2.4
2.3
mmol/l
0.53
98
476
51
210
2.80
8.88
6.1
6.4
0.3
1.4
mmol/l
0.76
39
166
42
178
2.64
6.84
5.5
3.2
—
—
—
0
0
180
1378
2.14
6.52
12.0
5.0
84.0
75.7
u/l
0.71
174
1256
43
189
2.55
6.50
3.1
2.5
9.1
7.3
umol/l
0.21
37
166
65
351
2.16
6.12
4.1
2.0
2.5
2.4
mmol/l
2.98
56
292
30
113
2.88
6.09
1.3
1.4
—
—
—
0
0
16
40
4.21
5.99
1.6
1.5
—
—
—
0
0
81
481
2.02
5.90
2.6
3.0
0.9
0.5
e6/l
0.31
59
356
14
33
4.44
5.63
2.4
2.9
4.0
3.7
g/l
0.20
14
33
95
613
1.90
5.34
2.8
3.1
—
—
—
0
0
9
8
11.62
5.33
2.0
1.5
13.0
19.1
ug/l
—
9
8
11
22
5.19
5.31
1.0
1.0
—
—
—
0
0
14
39
3.75
4.55
1.4
1.3
—
—
—
0
0
8
8
10.28
4.55
2.1
1.3
—
—
—
0
0
14
42
3.47
4.11
1.7
1.8
—
—
—
0
0
40
210
2.08
3.97
2.1
1.7
—
—
—
0
0
40
211
2.07
3.92
2.2
1.7
—
—
—
0
0
7
8
8.96
3.79
2.6
1.0
—
—
—
0
0
50
291
1.90
3.71
2.3
1.7
—
—
—
0
0
156
1834
0.59
3.67
3.7
4.8
1.4
1.4
mmol/l
0.31
141
1670
16
58
2.88
3.49
1.9
3.8
—
—
—
0
0
9
19
4.87
3.27
2.2
1.2
—
—
—
0
0
145
1161
1.61
3.25
4.2
4.4
391.9
5545.7
e6/l
—
7
18
160
1847
0.62
3.10
3.8
4.8
4.6
4.5
mmol/l
0.69
146
1689
20
87
2.41
3.10
1.6
1.3
4.2
5.8
ug/l
0.17
15
66
5
6
8.47
2.76
1.8
1.5
25.2
4.6
nmol/l
—
5
6
28
150
1.98
2.64
6.1
1.9
62.2
65.5
ml/min/173m2
0.24
13
56
154
1771
0.65
2.60
3.5
4.3
1.3
1.3
mmol/l
0.36
136
1599
22
110
2.10
2.50
6.2
7.9
0.7
0.7
%
0.02
22
110
79
578
1.54
2.47
3.3
2.1
48.2
56.8
u/l
2.45
74
530
168
1887
0.65
2.38
4.1
5.4
2.7
2.6
mmol/l
0.35
150
1721
21
111
1.98
2.08
6.2
7.9
1.5
1.6
%
0.19
21
111
166
1851
0.68
2.02
4.4
4.9
6.1
6.1
mmol/l
0.03
148
1657
5
11
4.61
1.95
1.0
1.1
—
—
—
0
0
9
34
2.71
1.88
2.0
1.6
—
—
—
0
0
8
31
2.63
1.67
1.1
1.5
—
—
—
0
0
6
19
3.21
1.67
2.2
1.5
—
—
—
0
0
35
506
0.64
1.65
1.2
1.7
1.5
1.4
mmol/l
0.28
28
423
19
106
1.86
1.64
1.8
1.5
—
—
—
0
0
19
319
0.56
1.64
1.0
1.3
15.2
37.3
iu/ml
—
5
104
5
14
3.62
1.62
2.6
1.6
—
—
—
0
0
6
20
3.05
1.59
2.0
1.5
—
—
—
0
0
8
33
2.47
1.55
2.1
1.5
—
—
—
0
0
198
1822
1.44
1.48
25.4
12.8
27.4
23.9
mg/l
0.86
175
1401
18
296
0.58
1.44
1.0
1.3
2.0
14.1
u/ml
—
5
109
9
41
2.24
1.38
1.4
1.2
—
—
—
0
0
6
23
2.65
1.37
2.0
1.4
—
—
—
0
0
5
17
2.98
1.36
1.8
2.1
—
—
—
0
0
16
91
1.81
1.32
2.8
2.9
0.4
0.2
e6/l
0.54
16
86
8
34
2.40
1.30
2.1
1.2
—
—
—
0
0
8
34
2.40
1.30
2.1
1.2
—
—
—
0
0
60
469
1.37
1.26
2.1
2.0
2.9
2.9
mg/l
0.05
53
391
6
25
2.43
1.25
2.3
1.6
—
—
—
0
0
5
19
2.66
1.22
1.2
1.7
—
—
—
0
0
5
19
2.66
1.22
2.6
1.7
—
—
—
0
0
32
225
1.49
1.20
1.7
2.4
21.1
23.1
%
0.36
27
194
59
470
1.34
1.10
3.8
4.2
0.0
0.0
estimate
0.00
25
139
25
353
0.68
1.06
1.2
1.3
6.0
1.8
u/ml
—
8
87
13
75
1.77
1.05
5.5
1.3
—
—
—
0
0
51
401
1.34
1.04
3.4
3.9
373.1
260.4
ng/l
0.21
45
324
5
22
2.30
1.04
2.6
1.5
—
—
—
0
0
176
1627
1.29
1.00
23.1
13.7
37.1
40.0
%
3.41
128
1087
18
116
1.60
0.99
1.2
1.2
103.3
132.8
iu/ml
—
6
45
17
255
0.64
0.97
3.6
5.0
31.6
31.7
%
0.02
11
162
0
32
0.00
0.96
0.0
1.4
—
—
—
0
0
25
176
1.47
0.95
2.5
3.5
212.9
203.5
ng/l
0.03
25
158
61
499
1.30
0.95
3.7
2.3
316.6
9250.5
umol/l
2.76
55
425
32
242
1.37
0.84
1.8
2.3
2.2
2.3
g/l
0.26
32
223
184
1726
1.26
0.83
24.1
11.6
83.4
76.7
ml/min/173m2
4.66
162
1378
36
279
1.34
0.82
2.7
2.9
3.4
2.4
e6/l
0.19
20
148
167
1781
0.81
0.81
5.2
6.6
40.2
40.7
mmol/mol
0.33
149
1635
33
423
0.75
0.81
2.5
2.6
0.7
0.8
ug/l
0.15
26
285
0
25
0.00
0.79
0.0
1.4
—
70.3
—
0
18
149
1373
1.22
0.76
4.5
3.8
14.5
15.0
pmol/l
1.39
143
1223
15
102
1.50
0.69
2.1
1.4
—
—
—
0
0
5
28
1.80
0.66
1.2
1.3
52.8
58.4
pmol/l
—
5
28
69
598
1.21
0.65
2.1
2.1
217.1
245.1
u/l
0.16
64
560
13
87
1.52
0.64
2.5
3.7
26.6
24.3
mmol/l
3.36
13
78
204
1955
1.25
0.64
26.2
15.7
4.0
4.0
mmol/l
0.80
199
1892
54
629
0.82
0.62
4.4
3.7
21.3
24.7
%
0.67
31
297
83
741
1.18
0.57
2.0
2.3
72.5
76.6
nmol/l
0.80
73
647
36
297
1.25
0.54
2.5
2.6
1.0
1.0
e6/l
0.06
19
167
25
199
1.29
0.50
2.0
2.8
7.6
8.0
ug/l
0.04
20
170
96
880
1.15
0.46
3.4
3.9
0.0
0.0
estimate
0.00
25
141
7
49
1.44
0.46
1.4
1.4
—
—
—
0
0
0
15
0.00
0.41
0.0
1.3
—
—
—
0
0
0
15
0.00
0.41
0.0
1.3
—
—
—
0
0
0
15
0.00
0.41
0.0
1.3
—
—
—
0
0
0
15
0.00
0.41
0.0
1.3
—
—
—
0
0
0
15
0.00
0.41
0.0
2.7
—
16.0
—
0
15
0
15
0.00
0.41
0.0
1.3
—
—
—
0
0
0
16
0.00
0.41
0.0
1.1
—
—
—
0
0
0
17
0.00
0.41
0.0
1.1
—
—
—
0
0
8
111
0.71
0.38
1.5
1.7
—
—
—
0
0
43
377
1.17
0.37
1.8
1.7
2.3
1.1
mg/l
1.09
36
291
45
399
1.16
0.34
1.9
1.7
1116.8
1177.6
nmol/l
0.16
34
290
14
111
1.28
0.30
1.5
1.8
—
—
—
0
0
77
824
0.90
0.27
2.2
1.9
87.6
93.8
pmol/l
0.68
39
420
8
65
1.24
0.27
2.0
1.4
—
—
—
0
0
5
71
0.70
0.26
1.0
2.5
27.4
43.1
u/l
—
5
64
17
201
0.83
0.24
1.5
1.4
—
—
—
0
0
15
124
1.22
0.24
1.7
2.0
—
—
—
0
0
95
901
1.09
0.23
3.5
3.9
0.0
0.0
estimate
0.00
25
137
74
787
0.91
0.23
4.0
3.8
3.3
2.0
ug/l
0.42
68
695
76
807
0.92
0.23
3.8
3.9
858.4
86.8
ng/l
0.46
54
578
17
144
1.19
0.22
2.1
2.8
5.3
4.3
kpa
0.64
17
138
93
884
1.08
0.22
4.4
5.1
0.0
0.0
estimate
0.00
25
142
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.3
—
—
—
0
0
0
12
0.00
0.21
0.0
1.4
—
—
—
0
0
0
13
0.00
0.21
0.0
1.8
—
—
—
0
0
6
48
1.26
0.20
1.0
1.3
—
—
—
0
0
0
14
0.00
0.20
0.0
1.7
—
—
—
0
0
0
14
0.00
0.20
0.0
2.9
—
805.0
—
0
14
6
50
1.20
0.20
1.7
2.3
—
—
—
0
0
6
51
1.18
0.19
1.2
1.2
—
—
—
0
0
40
432
0.91
0.17
1.8
1.7
420.9
16765135.5
pmol/l
0.50
33
340
8
71
1.13
0.16
2.3
1.5
—
—
—
0
0
5
46
1.09
0.09
1.2
1.3
—
—
—
0
0
13
116
1.13
0.09
1.2
1.3
—
35.4
—
0
10
73
707
1.05
0.09
3.8
3.9
—
—
—
0
0
64
620
1.04
0.08
2.9
3.1
1728.4
1610.7
ng/l
0.05
58
521
207
2053
1.05
0.07
33.2
18.6
4.2
4.5
e12/l
11.93
200
1975
25
236
1.07
0.06
1.2
1.4
—
—
—
0
0
98
962
1.03
0.06
2.7
2.6
—
—
—
0
0
139
1376
1.02
0.04
4.6
4.1
17.9
12.1
mm/h
3.49
134
1253
75
741
1.02
0.02
2.4
2.6
213.5
129.9
ug/l
1.27
69
673
172
1711
1.02
0.02
5.2
4.6
2.1
1.9
mu/l
0.89
159
1530
26
262
0.99
0.00
9.6
7.4
—
—
—
0
0
113
1127
1.00
0.00
3.0
3.0
48.0
48.1
u/l
0.00
105
1047
0
8
0.00
0.00
0.0
1.0
—
9.3
—
0
8
7
75
0.93
0.00
1.1
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
9
98
0.92
0.00
2.1
2.4
0.8
1.3
%
—
9
98
0
5
0.00
0.00
0.0
2.4
—
1.3
—
0
5
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
6
65
0.92
0.00
1.5
2.5
—
—
—
0
0
0
8
0.00
0.00
0.0
2.1
—
—
—
0
0
0
9
0.00
0.00
0.0
1.3
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: C3_NASAL_CAVITY_MIDDLE_EAR_EXALLC – Malignant neoplasm of nasal cavity and middle ear, excluding all cancers (controls excluding all cancers)
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).